News
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo
Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) are engaged in a battle of sorts. The two won FDA approval for new non-small cell lung cancer therapies in 2015 that work similarly, and
Merck's Keytruda Plays Catch-Up to Bristol-Myers' Opdivo
Merck & Co (NYSE: MRK) and Bristol-Myers Squibb (NYSE: BMY) are engaged in a battle of sorts. The two won FDA approval for new non-small cell lung cancer therapies in 2015 that work similarly, and
Here's Why the Best Is Yet to Come for Exact Sciences
Millions of Americans forego getting tested for colon cancer; however, a new colon cancer test from Exact Sciences (NASDAQ: EXAS) is changing that, and as a result, patients are catching their cancer
The Single Best Reason to Buy Novavax Stock Now
Buy the rumor and sell the news doesn't always work out so well. Investors who followed the old adage with Novavax (NASDAQ: NVAX) recently learned that lesson the hard way. Shares of the
12 Numbers in Pfizer's Q2 Update More Important Than Its Revenue Decline
Pfizer (NYSE: PFE) announced its second-quarter results before the market opened on Tuesday. And investors yawned -- at least for the most part.Many of the headlines about the big drugmaker's
12 Numbers in Pfizer's Q2 Update More Important Than Its Revenue Decline
Pfizer (NYSE: PFE) announced its second-quarter results before the market opened on Tuesday. And investors yawned -- at least for the most part.Many of the headlines about the big drugmaker's
Here's Why Geron Corporation Fell as Much as 16.6% Today
Shares of clinical stage biopharma Geron Corporation (NASDAQ: GERN) fell nearly 17% Tuesday after management provided a clinical update on its only drug candidate, imetelstat, which is being
2 Dividend-Growth Stocks That Are Minting Money
If you're looking for a good dividend stock for the long term, it's important to look beyond current dividend yields to the company's prospects for growth and the strength of its free cash flow. A
2 Dividend-Growth Stocks That Are Minting Money
If you're looking for a good dividend stock for the long term, it's important to look beyond current dividend yields to the company's prospects for growth and the strength of its free cash flow. A
Evotec: Rekordübernahme!
Wieder gute News vom Wirkstoffhersteller Evotec. Wie das Unternehmen mitteilt, soll der US-Konkurrent Aptuit für rund 300 Mio. USD übernommen werden. Das ist der größte Zukauf in der....
Why Clovis Oncology Tumbled 13.5% Today
After disclosing that it's entered into a pact with Bristol-Myers Squibb (NYSE: BMY) on its cancer-fighting drug Rubraca, shares in Clovis Oncology (NASDAQ: CLVS) lost 13.5% of their value Monday.
Why Clovis Oncology, Gulfport Energy, and Hertz Global Holdings Slumped Today
The stock market saw a lot of indecision on Monday, as major benchmarks moved in different directions. The Nasdaq Composite was weaker than most of its peers, but the Dow Jones Industrials jumped to
Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing)
Seattle Genetics (NASDAQ: SGEN) reported second-quarter revenue and earnings numbers, but the conference call focused mostly on potential near-term revenue growth for the biotech's one approved drug
Seattle Genetics, Inc.: Expanded Sales on Their Way (FDA Willing)
Seattle Genetics (NASDAQ: SGEN) reported second-quarter revenue and earnings numbers, but the conference call focused mostly on potential near-term revenue growth for the biotech's one approved drug
ImmunoGen, Inc. Earnings: What Goes Up, Must Come Down
After popping 14% on Friday follow earnings that didn't justify the increase, shares of ImmunoGen (NASDAQ: IMGN) are down 12.6% at 2:49 p.m. EDT on Monday, also for no apparent reason. The biotech
A Beat From Qiagen NV, but Only Half a Raise
It was another solid quarter for Qiagen (NASDAQ: QGEN) as the maker of diagnostic and scientific products continues to post decent revenue growth while getting more efficient, which drives income to
Up 81.6%: Is Dynavax Technologies Corporation Stock Still a Buy?
Dynavax Technologies Corporation (NASDAQ: DVAX) stock jumped a whopping 81.6% in after-hours trading Friday because of a favorable 12-to-1 advisory committee vote for its experimental hepatitis-B
Better Buy: Cara Therapeutics Inc. vs. GW Pharmaceuticals plc
Cara Therapeutics Inc. (NASDAQ: CARA), and GW Pharmaceuticals plc (NASDAQ: GWPH) often get lumped in with a stack of risky marijuana stocks, because both are developing drugs derived from the
3 Things You Can Expect With Pfizer's Q2 Results
There was good news and bad news for Pfizer (NYSE: PFE) the last time it reported quarterly results. In May, the big drugmaker announced earnings for the first quarter that beat analysts' estimates
3 Things You Can Expect With Pfizer's Q2 Results
There was good news and bad news for Pfizer (NYSE: PFE) the last time it reported quarterly results. In May, the big drugmaker announced earnings for the first quarter that beat analysts' estimates
What's Next for AstraZeneca and Its Dividend?
Just over three summers ago, AstraZeneca plc (NYSE: AZN) CEO Pascal Soriot convinced shareholders to reject a generous buyout offer from Pfizer with promises that drugs in its pipeline would deliver
What's Next for AstraZeneca and Its Dividend?
Just over three summers ago, AstraZeneca plc (NYSE: AZN) CEO Pascal Soriot convinced shareholders to reject a generous buyout offer from Pfizer with promises that drugs in its pipeline would deliver
3 Biotech Stocks for Enterprising Investors
The biotech sector isn't for the faint of heart. While investors can strike it rich if they get lucky, they can also lose a bundle if things don't go according to plan. Given the risk, it can take a
McCain Pulls the Plug on Obamacare "Skinny Repeal" Without Replacement
Republicans have been fighting to repeal and replace the Affordable Care Act since it was passed by Democrats in 2010. After winning Congress and the White House last November, many republicans
McCain Pulls the Plug on Obamacare "Skinny Repeal" Without Replacement
Republicans have been fighting to repeal and replace the Affordable Care Act since it was passed by Democrats in 2010. After winning Congress and the White House last November, many republicans